The cancer products portfolio that DARA BioSciences (NASDAQ:DARA) has been building by acquisition now has more than $9 million in fresh capital to help bring those products to market. The ...

According to a DARA regulatory filing, Uman is responsible for formulation, analytical and manufacturing work on the drug. Uman must also make the abbreviated new drug application for U.S. marketing ...

DARA BioSciences (Nasdaq: DARA) as the clinical-stage pharmaceutical company acquires the product in a move that positions the company to sell and develop products for the lucrative cancer drug market ...

RALEIGH, N.C.--(BUSINESS WIRE)-- DARA BioSciences, Inc. (NAS: DARA) (the "Company" or "DARA") announced that it entered into a definitive securities purchase agreement with certain investors providing ...

DARA BioSciences (NASDAQ:DARA), which earlier this week acquired cancer therapeutics firm Oncogenerix, has made yet another deal, this one an agreement to raise $1.7 million in a private placement.

DARA Biosciences, Inc. ( DARA) recently entered into an exclusive distribution agreement with Seyer Pharmatec Inc. to sell and distribute the breast cancer product Soltamox in the Commonwealth of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Dara Biosciences (Nasdaq: DARA) has found a way to further ...

Since its approval in 1977, tamoxifen has been used to treat millions of women and men diagnosed with hormone-receptor-positive breast cancer. Treatment with tamoxifen lowers the risk of breast cancer ...